Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Large Employers, Insurers, PCMA Ask CMS To Retain Formulary Tools

This article was originally published in The Pink Sheet Daily

Executive Summary

A group of large employers, insurance companies and the Pharmaceutical Care Management Association has sent a letter to the Centers for Medicare & Medicaid Services arguing that the Medicare drug benefit should permit a wide range of cost effectiveness tools

You may also be interested in...

PCMA Launches Ad Campaign On Medicare Formulary Design

Print ad asks "Guess who's coming to dinner?" and features a sumo wrestler representing "the big drug companies." Inside-the-Beltway advertising campaign is designed to ensure that Medicare Rx formulary design permits current market practices, the PBM association says.

Generic Association CEO Davis Jumps To Wholesalers Group

Association for Accessible Medicines’ interim leader is General Counsel Jeffrey Francer; Chip Davis’ four-and-half year tenure included a total rebrand of the association, a significant legislative victory with the CREATES act – and an abrupt departure for the Healthcare Distribution Alliance.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts